Skip to Content

Juniper Pharmaceuticals, Inc. (JNP)

Merger

Overview
  • Date:
  • 7/5/2018
  • Company Name:
  • Juniper Pharmaceuticals, Inc.
  • Stock Symbol:
  • JNP
  • Company Name - Buyer:
  • Catalent Inc.
  • Status:
  • Closed/Complete

Case Finder

Locate any case using the tools below.

NEW YORK, July 5, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Juniper Pharmaceuticals, Inc. (NASDAQ: JNP) stockholders concerning the proposed acquisition of the company by Catalent Inc.

Pursuant to the proposed transaction, valued at approximately $5.58B, Juniper shareholders will receive $11.50 in cash for each of their Juniper Pharmaceuticals shares.  Our investigation concerns whether the Juniper Pharmaceuticals board of directors failed to adequately shop the Company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Catalent.

If you own Juniper Pharmaceuticals shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: